Press Room

Visit our press room for current and past releases about our company.
December 11, 2013

Algorithme Pharma Gains Key Patient Access Through Partnership with Hôpital Maisonneuve-Rosemont (HMR)

Algorithme Pharma, a leading early stage clinical research organization, is pleased to offer sponsors increased patient access in key therapeutic areas through the strategic partnership with Hôpital Maisonneuve-Rosemont (HMR).

October 29, 2013

Algorithme Pharma Signs Strategic Alliance with University of Montreal Hospital Research Centre (CRCHUM)

Algorithme Pharma is pleased to announce the signing of a strategic alliance with the University of Montreal Hospital Research Centre (CRCHUM), allowing for access to an extensive pool of patients and the new 520,000 sq. ft. research complex (CRCHUM) for conducting complex early stage clinical trials.

May 14, 2013

Vince and Associates Clinical Research Joins the Altasciences Group

(Laval, Québec, Canada May 14, 2013) – The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.

March 24, 2013

SQI Diagnostics and Algorithme Pharma Provide Update on Multiplex Heparin Immunogenicity Assay

Collaborative results recently presented at the 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore 18-20 March

TORONTO - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), and Algorithme Pharma (“Algorithme”) today announced that they have completed the multiplexed proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds using SQI’s Ig_PLEX™ multiplexing technology.

February 13, 2013

Lab Bio-Medic, Algorithme Pharma Sign Partnership

Montreal, February 14, 2013 – Lab Bio-Medic and Algorithme Pharma are pleased to announce that they have signed a partnership agreement for the delivery of biomedical analysis required as part of clinical research projects conducted on behalf of pharmaceutical and biotech customers of this world leader in the conduct of Phase I / IIa and bioequivalence clinical trials.